X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (750) 750
Publication (10) 10
Patent (3) 3
Book Chapter (2) 2
Book Review (1) 1
Newsletter (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (361) 361
cardiac & cardiovascular systems (303) 303
male (225) 225
female (219) 219
abridged index medicus (188) 188
aged (178) 178
middle aged (149) 149
cardiovascular (134) 134
treatment outcome (113) 113
risk factors (110) 110
cardiology (108) 108
heart attacks (102) 102
care and treatment (88) 88
mortality (87) 87
stroke (86) 86
cardiovascular disease (76) 76
atrial fibrillation (75) 75
patients (67) 67
percutaneous coronary intervention (67) 67
internal medicine (66) 66
usage (66) 66
cardiology and cardiovascular medicine (65) 65
warfarin (57) 57
peripheral vascular disease (55) 55
angiography (54) 54
outcomes (54) 54
stroke - prevention & control (54) 54
coronary heart disease (53) 53
rivaroxaban (53) 53
anticoagulants (52) 52
management (52) 52
clinical trials (51) 51
united states (51) 51
risk (49) 49
atrial fibrillation - drug therapy (48) 48
coronary vessels (47) 47
aged, 80 and over (46) 46
analysis (46) 46
angioplasty (46) 46
prevention (46) 46
drug therapy (45) 45
heart failure (45) 45
medicine, general & internal (45) 45
retrospective studies (45) 45
risk assessment (45) 45
surgery (45) 45
double-blind method (44) 44
coronary artery disease (43) 43
myocardial infarction (43) 43
patient outcomes (42) 42
heart (41) 41
clinical outcomes (40) 40
ischemia (40) 40
time factors (40) 40
acute coronary syndromes (39) 39
cardiac patients (39) 39
atrial fibrillation - complications (38) 38
follow-up studies (38) 38
heart attack (38) 38
prospective studies (38) 38
disease (37) 37
intervention (37) 37
medical imaging (37) 37
adult (36) 36
diagnosis (36) 36
therapy (35) 35
united states - epidemiology (35) 35
coronary angiography (34) 34
hypertension (34) 34
stroke - etiology (34) 34
peripheral artery disease (33) 33
imaging (32) 32
medical research (31) 31
multimodality (31) 31
acute myocardial-infarction (30) 30
blood pressure (30) 30
cardiovascular diseases (30) 30
heart diseases (30) 30
revascularization (30) 30
task-force (30) 30
anticoagulants - therapeutic use (29) 29
health aspects (29) 29
prognosis (29) 29
incidence (28) 28
patient selection (28) 28
warfarin - administration & dosage (28) 28
anticoagulants - administration & dosage (27) 27
cardiac arrhythmia (27) 27
diabetes (27) 27
hospitals (27) 27
medical colleges (27) 27
medicine, experimental (27) 27
predictive value of tests (27) 27
accf appropriate use criteria (26) 26
clopidogrel (26) 26
coronary artery disease - diagnosis (26) 26
radiology, nuclear medicine & medical imaging (26) 26
registries (26) 26
studies (26) 26
warfarin - therapeutic use (26) 26
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 1, pp. 32 - 40
Journal Article
Lancet neurology, ISSN 1474-4422, 2012, Volume 11, Issue 4, pp. 315 - 322
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 10, pp. 883 - 891
In this trial, 14,264 patients with atrial fibrillation were randomly assigned to receive either rivaroxaban or warfarin. In a per-protocol, as-treated... 
NON-INFERIORITY | ENOXAPARIN | MEDICINE, GENERAL & INTERNAL | DABIGATRAN | STROKE PREVENTION | PHARMACOKINETICS | EFFICACY | ANTITHROMBOTIC THERAPY | PHARMACODYNAMICS | THROMBOPROPHYLAXIS | ANTICOAGULATION | Thiophenes - therapeutic use | Thiophenes - adverse effects | Humans | Middle Aged | Warfarin - adverse effects | Male | Thiophenes - administration & dosage | Warfarin - administration & dosage | Warfarin - therapeutic use | Rivaroxaban | Aged, 80 and over | Female | Stroke - epidemiology | Embolism - epidemiology | Morpholines - adverse effects | Morpholines - therapeutic use | Stroke - prevention & control | Embolism - prevention & control | Double-Blind Method | Administration, Oral | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Intention to Treat Analysis | Aged | Hemorrhage - chemically induced | Stroke (Disease) | Warfarin | Atrial fibrillation | Patient outcomes | Dosage and administration | Drug therapy | Comparative analysis | Risk factors | Fees & charges | Cardiac arrhythmia | Stroke | Heart attacks | Research & development--R&D | Embolisms | Equity | Equity stake | Hemorrhage | Bleeding | Embolism | Studies | Prevention | Fibrillation | Motivation | Ischemia | Thromboembolism | Drug dosages | Pharmaceuticals | Anticoagulants | Morpholines | Life Sciences | Thiophenes | Atrial Fibrillation
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2013, Volume 61, Issue 19, pp. 1998 - 2006
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2016, Volume 67, Issue 24, pp. 2888 - 2899
Abstract Nonvitamin K-dependent oral anticoagulant agents (NOACs) are currently recommended for patients with atrial fibrillation at risk for stroke. As a... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | apixaban | stroke | edoxaban | renal dialysis | CARDIAC & CARDIOVASCULAR SYSTEMS | APPENDAGE CLOSURE | PLATELET-AGGREGATION | SAFETY | PHARMACOKINETICS | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | HEMODIALYSIS-PATIENTS | NONVALVULAR ATRIAL-FIBRILLATION | STAGE RENAL-DISEASE | WARFARIN USE | Pyrazoles - therapeutic use | Dabigatran - pharmacokinetics | Humans | Pyridines - pharmacokinetics | Renal Insufficiency, Chronic - complications | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - pharmacokinetics | Warfarin - therapeutic use | Renal Insufficiency, Chronic - therapy | Kidney - metabolism | Pyrazoles - pharmacokinetics | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Stroke - prevention & control | Glomerular Filtration Rate | Pyridones - pharmacokinetics | Atrial Fibrillation - drug therapy | Anticoagulants - therapeutic use | Creatinine - urine | Warfarin - pharmacokinetics | Kidney Failure, Chronic - therapy | Rivaroxaban - pharmacokinetics | Kidney Failure, Chronic - complications | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Hemorrhage - chemically induced | Renal Dialysis | Stroke (Disease) | Medical colleges | Care and treatment | Continuing medical education | Warfarin | Chronic kidney failure | Atrial fibrillation | Mortality | Medical care | Quality management | Urine | Confidence intervals | Disease prevention | Anticoagulants | Stroke | Hemodialysis | Kidney diseases | Metabolism | Drug dosages
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 167, Issue 6, pp. 846 - 852.e2
Journal Article
Journal Article